Goldman Sachs Group Inc. reiterated their conviction-buy rating on shares of Shire PLC (LON:SHP) in a report released on Thursday. They currently have a GBX 6,300 ($82.23) price objective on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued reports about the company. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,600 ($73.10) price target on shares of Shire PLC in a research report on Monday, June 13th. Royal Bank Of Canada reaffirmed an outperform rating on shares of Shire PLC in a research report on Friday, July 22nd. JPMorgan Chase & Co. reaffirmed an overweight rating and set a GBX 6,300 ($82.23) price target on shares of Shire PLC in a research report on Tuesday, August 16th. Jefferies Group increased their price target on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the stock a buy rating in a research report on Wednesday, August 3rd. Finally, Citigroup Inc. reaffirmed a buy rating on shares of Shire PLC in a research report on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5001.00 on Thursday. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The stock’s market cap is GBX 34.15 billion. The firm’s 50-day moving average price is GBX 4,985.30 and its 200-day moving average price is GBX 4,508.27.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 8th will be paid a GBX 3.51 ($0.05) dividend. This represents a yield of 0.07%. The ex-dividend date of this dividend is Thursday, September 8th.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.